Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen presented as a 52 mg intrauterine system (IUS) for intrauterine use. It provides long‑acting hormonal contraception and is also indicated for the management of heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring regulatory‑approved quality for global distribution. The product is manufactured for the European Union market and meets EU pharmacovigilance standards, and is distributed under strict quality‑assurance protocols.

Levonorgestrel in Mirena acts on the reproductive hormonal axis to provide contraception and control menstrual bleeding.

Contraception: offers a reversible, long‑acting method that prevents pregnancy for up to five years. Heavy menstrual bleeding: reduces menstrual blood loss and improves quality of life in women with symptomatic HMB. Menstrual regulation: stabilises menstrual cycles and can lessen dysmenorrhoea associated with irregular bleeding.

Levonorgestrel released from Mirena may cause a range of adverse reactions.

Common Side Effects: - Irregular bleeding or spotting, especially in the first months. - Amenorrhea (absence of periods) after prolonged use. - Pelvic or abdominal cramping. - Breast tenderness or mild hormonal acne. - Mood changes or headache.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic inflammatory infection. - Ectopic pregnancy if conception occurs. - Ovarian cyst formation. - Device migration to adjacent organs.

Before Mirena insertion, clinicians should assess patient suitability and counsel on potential risks.

Screen for contraindications: ensure no active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel. Pregnancy testing: confirm the patient is not pregnant prior to placement. Follow‑up schedule: arrange a pelvic examination 4–6 weeks after insertion to verify position. Device removal planning: schedule removal or replacement after five years or earlier if clinical circumstances change. Interaction with hormonal therapies: avoid concurrent use of systemic estrogen products unless medically indicated. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena can be affected by other medicines that alter hormone metabolism or uterine environment.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants such as carbamazepine or phenytoin, which may lower levonorgestrel efficacy. - Concurrent use of systemic estrogen‑containing contraceptives that could disrupt local hormone balance.

Moderate Interactions (Monitor Closely): - Rifampin and other strong enzyme inducers that may reduce device effectiveness. - Azole antifungals (e.g., ketoconazole) that could increase levonorgestrel levels. - Hormone replacement therapy that may modify bleeding patterns. - Uterine cavity‑distorting devices that could affect proper placement.